Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
NCT ID: NCT02865850
Last Updated: 2022-07-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
369 participants
INTERVENTIONAL
2016-07-31
2020-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
NCT02892149
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
NCT02680574
Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents
NCT03140722
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
NCT02648347
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
NCT03799627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vadadustat
Vadadustat
Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Darbepoetin alfa
Darbepoetin alfa
Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vadadustat
Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Darbepoetin alfa
Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Initiated chronic maintenance dialysis (either peritoneal or hemodialysis) for end-stage kidney disease within 16 weeks prior to Screening
* Mean Screening hemoglobin between 8.0 and \<11.0 grams per deciliter (g/dL) (inclusive)
* Serum ferritin ≥100 nanograms per deciliter (ng/mL) and TSAT ≥20% during Screening
Exclusion Criteria
* Red blood cells transfusion within 8 weeks prior to randomization
* Anticipated to recover adequate kidney function to no longer require dialysis
* Uncontrolled hypertension
* Severe heart failure at Screening (New York Heart Association Class IV)
* Acute coronary syndrome (hospitalization for unstable angina, myocardial infarction); surgical or percutaneous intervention for coronary, cerebrovascular, or peripheral artery disease (aortic or lower extremity); surgical or percutaneous valvular replacement or repair; sustained ventricular tachycardia; hospitalization for congestive heart failure; or stroke within 12 weeks prior to or during Screening.
* Participants meeting the criteria of erythropoiesis-stimulating agent resistance within 8 weeks prior to or during Screening defined as follows
1. epoetin: \> 7700 units/dose three times per week or \>23,000 units per week
2. Darbepoetin alfa: \>100 micrograms per week (mcg/week)
3. methoxy polyethylene glycol-epoetin beta: \>100 micrograms (mcg) every other week or \>200 mcg/month
* Hypersensitivity to Vadadustat, Darbepoetin alfa or any of their excipients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Akebia Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chief Medical Officer
Role: STUDY_DIRECTOR
Akebia Therapeutics Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Huntsville, Alabama, United States
Research Site
Mesa, Arizona, United States
Research Site
Anaheim, California, United States
Research Site
Canyon Country, California, United States
Research Site
Downey, California, United States
Research Site
Glendale, California, United States
Research Site
Granada Hills, California, United States
Research Site
La Mesa, California, United States
Research Site
Long Beach, California, United States
Research Site
Los Angeles, California, United States
Research Site
Montebello, California, United States
Research Site
Monterey Park, California, United States
Research Site
Newhall, California, United States
Research Site #1
Northridge, California, United States
Research Site #2
Northridge, California, United States
Research Site
Riverside, California, United States
Research Site
Riverside, California, United States
Research Site
Sacramento, California, United States
Research Site
San Diego, California, United States
Research Site
San Dimas, California, United States
Research Site
Whittier, California, United States
Research Site
Arvada, Colorado, United States
Research Site
Westminster, Colorado, United States
Research Site
Stamford, Connecticut, United States
Research Site
Coral Gables, Florida, United States
Research Site
Coral Springs, Florida, United States
Research Site
Lauderdale Lakes, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami Beach, Florida, United States
Research Site
Winter Park, Florida, United States
Research Site
Augusta, Georgia, United States
Research Site
Columbus, Georgia, United States
Research Site #2
Lawrenceville, Georgia, United States
Research Site
Statesboro, Georgia, United States
Research Site
Meridian, Idaho, United States
Research Site
Takoma Park, Maryland, United States
Research Site
Roseville, Michigan, United States
Research Site
Kansas City, Missouri, United States
Research Site
Albuquerque, New Mexico, United States
Research Site
Astoria, New York, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site #1
Chattanooga, Tennessee, United States
Research Site #2
Chattanooga, Tennessee, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Nashville, Tennessee, United States
Research Site
Arlington, Texas, United States
Research Site
El Paso, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Houston, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Hampton, Virginia, United States
Research Site
Bahía Blanca, Buenos Aires, Argentina
Research Site
Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina
Research Site
Junín, Buenos Aires, Argentina
Research Site
Pergamino, Buenos Aires, Argentina
Research Site
Temperley, Buenos Aires, Argentina
Research Site
Corrientes, , Argentina
Research Site
Córdoba, , Argentina
Research Site
Salta, , Argentina
Research Site
San Luis, , Argentina
Research Site
Fortaleza, Ceará, Brazil
Research Site
Belo Horizonte, Minas Gerais, Brazil
Research Site
Juiz de Fora, Minas Gerais, Brazil
Research Site
Curitiba, Paraná, Brazil
Research Site
Maringá, Paraná, Brazil
Research Site
Canoas, Rio Grande do Sul, Brazil
Research Site
Passo Fundo, Rio Grande do Sul, Brazil
Research Site
Porto Alegre, Rio Grande do Sul, Brazil
Research Site
Porto Alegre, Rio Grande do Sul, Brazil
Research Site
Joinville, Santa Catarina, Brazil
Research Site
Santo André, São Paulo, Brazil
Research Site
São Bernardo do Campo, São Paulo, Brazil
Research Site
São Paulo, São Paulo, Brazil
Research Site
Villingen-Schwenningen, Baden-Wurttemberg, Germany
Research Site
Rostock, Mecklenburg-Vorpommern, Germany
Research Site
Düsseldorf, North Rhine-Westphalia, Germany
Research Site
San Giovanni Rotondo, Foggia, Italy
Research Site
Genova, , Italy
Research Site
Lecco, , Italy
Research Site
Napoli, , Italy
Research Site
Pavia, , Italy
Research Site
Roma, , Italy
Research Site
Siena, , Italy
Research Site
Zapopan, Jalisco, Mexico
Research Site
Morelia, Michoacán, Mexico
Research Site
Culiacán, Sinaloa, Mexico
Research Site
Golub-Dobrzyń, , Poland
Research Site
Lodz, , Poland
Research Site
Lodz, , Poland
Research Site
Leiria, , Portugal
Research Site
Loures, , Portugal
Research Site #2
Kemerovo, , Russia
Research Site
Krasnoyarsk, , Russia
Research Site
Moscow, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Chuncheon, Gangwon-do, South Korea
Research Site
Seongnam-si, Gyeonggi-do, South Korea
Research Site
Busan, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Brovary, , Ukraine
Research Site
Cherkassy, , Ukraine
Research Site
Dnipro, , Ukraine
Research Site
Ivano-Frankivsk, , Ukraine
Research Site
Kharkiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Mykolaiv, , Ukraine
Research Site
Ternopil, , Ukraine
Research Site
Uzhhorod, , Ukraine
Research Site
Vinnytsia, , Ukraine
Research Site
Zaporizhzhia, , Ukraine
Research Site
Zhytomyr, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chertow GM, Eckardt KU, Sarnak MJ, Winkelmayer WC, Agarwal R, Minga T, Luo W, Burke SK. Safety and Efficacy of Vadadustat for the Treatment of CKD-Related Anemia within and outside the United States. J Am Soc Nephrol. 2025 Oct 1;36(10):1984-1997. doi: 10.1681/ASN.0000000708. Epub 2025 May 13. No abstract available.
Sarnak MJ, Agarwal R, Boudville N, Chowdhury PCP, Eckardt KU, Gonzalez CR, Kooienga LA, Koury MJ, Ntoso KA, Luo W, Parfrey PS, Vargo DL, Winkelmayer WC, Zhang Z, Chertow GM. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023 Sep 29;38(10):2358-2367. doi: 10.1093/ndt/gfad074.
Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
Eckardt KU, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, Farag YMK, Fishbane S, Hubert H, Jardine A, Khawaja Z, Koury MJ, Maroni BJ, Matsushita K, McCullough PA, Lewis EF, Luo W, Parfrey PS, Pergola P, Sarnak MJ, Spinowitz B, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Zwiech R, Chertow GM. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 Apr 29;384(17):1601-1612. doi: 10.1056/NEJMoa2025956.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-000838-21
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AKB-6548-CI-0016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.